Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for GEFS+ and Cardiac Arrhythmia Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SCN1B drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SCN1B ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View SCN1B Products |
| Gene Delivery | SCN1B Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View SCN1B Products |
| Benchmark Ab | Anti-SCN1B (Research Grade) Recombinant positive control. |
View SCN1B Products |
| Validator | SCN1B siRNA Set For knockdown verification. |
View SCN1B Products |
| Related Target A | SCN1A Alpha subunit partner for epilepsy models. |
View SCN1A Products |
| Related Target B | SCN5A Alpha subunit partner for cardiac arrhythmia models. |
View SCN5A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Membrane Protein Conformation | Lentivirus premade particles for stable cell line generation (Crucial for patch-clamp assays) |
| Extracellular Domain Targeting | High purity (>95%) ECD-Fc fusion proteins expressed in HEK293 for native glycosylation |
| Lack of Controls | Recombinant positive control antibodies included |
| False Positives | Validated siRNA included for specificity checks |
Live SCN1B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SCN1B therapeutics is focused on its critical role as a beta-1 subunit modulating voltage-gated sodium channels (Nav). Mutations in SCN1B are directly linked to Generalized Epilepsy with Febrile Seizures Plus (GEFS+), idiopathic childhood epilepsy, and cardiac conditions like Brugada syndrome. As first-generation therapies targeting alpha subunits reach the clinic, the next wave of R&D is targeting beta subunits like SCN1B to indirectly modulate channel kinetics and cell adhesion functions.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecules | Early-stage Biotech | GEFS+, Epilepsy | Electrophysiology (Need Lentivirus for stable cells) |
| Gene Therapy | Academic Consortia | Brugada Syndrome | Expression Validation (Need specific Antibodies) |
| Monoclonal Antibodies | Preclinical R&D | Neurological Disorders | Binding Assays (Need high-purity ECD-Fc) |